PCYC

February 5, 2012

Past Pitfalls and Potential Promise for Pancreatic Cancer

October 25, 2010 By MD Becker Partners Leave a Comment

pancreatic_slide

Next month [November] marks Pancreatic Cancer Awareness Month. Visibility for the disease is already on the rise due to recent celebrity victims, including Apple’s Steve Jobs and Hollywood actor Patrick Swayze. According to the American Cancer Society, pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower [...]

Filed Under: Articles Tagged With: 90Y-hPAM4, AAPL, Abraxane, Abraxis BioScience, Afinitor, ALPMY.PK, AMG 479, Amgen, AMGN, Aphton Corp, Apple, ASG-5ME, Astellas Pharma, Bayer Schering Pharma AG, BioSante Pharmaceuticals, BPAX, CA19-9, CDX-1307, CELG, Celgene Corporation, Celldex Therapeutics, CLDX, Clivatuzumab tetraxetan, Eli Lilly, ensituximab, everolimus, gemcitabine, Gemzar, GenVec, GI-4000, GlobeImmune, GNVC, GVAX, ImClone Systems, IMMU, Immunomedics, INFI, Infinity Pharma, IPI-926, LLY, Neogenix Oncology, Neuroendocrine tumors, Novartis, NPC-1C, NVS, Oncolytics Biotech, ONCY, paclitaxel, pancreatic cancer, Patrick Swayze, PCI-27483, PCYC, PFE, Pfizer, Pharmacyclics, PTK787, Regeneron Pharmaceuticals, REGN, Roche Holdings, Sanofi-Aventis, SciClone Pharmaceuticals, SCLN, Seattle Genetics, SGEN, SNY, Steve Jobs, SuperGen, SUPG, TH-302, Therion Biologics, THLD, Threshold Pharmaceuticals, Vatalanib, ZK-222584)

Biotech Baker’s Dozen to Watch at Hematology Meeting

November 29, 2009 By MD Becker Partners 2 Comments

The 51st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation (CELG) recently announced that data from [...]

Filed Under: Articles Tagged With: AEterna Zentaris, AEZS, Allos Therapeutics, ALTH, American Society of Hematology, ARIA, ARIAD Pharmaceuticals, Calistoga Pharmaceuticals, CELG, Celgene, chemotherapeutics, CYCC, Cyclacel Pharmaceuticals, Facet Biotech, FACT, GENT, Gentium SPA, HDAC inhibitors, IMGN, ImmunoGen, KaloBios Pharmaceuticals, kerx, Keryx Biopharmaceuticals, kinase inhibitors, monoclonal antibodies, nucleoside analogues, ONXX, Onyx Pharmaceuticals, PCYC, Pharmacyclics, pi3k, proteasome inhibitors, sapacitabine, Seattle Genetics, Semafore Pharmaceuticals, SGEN, small modular immunopharmaceuticals, SNSS, Sunesis Pharmaceuticals, TRBN, Trubion Pharmaceuticals